Figure 1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors

Best change in tumor size from baseline for (A) IPH5201 monotherapy (n = 38) and (B) IPH5201 + durvalumab (n = 19). Patients who developed new lesion as defined per RECIST v1.1 are denoted by an asterisk (*). Data are shown based on the as-treated population, defined as all patients who received any investigational product. ad, adenocarcinoma; CRC, colorectal cancer; NSCLC, non-small cell lung cancer; PDAC, pancreatic ductal adenocarcinoma; SCC, squamous cell carcinoma; sq, squamous.